ATCC and the Broad Institute of MIT and Harvard today announced new research describing the development of engineered ...
Genomic profiles and treatment outcomes in young adults with stage IV non-small cell lung cancer (NSCLC): Insights from the Middle East. Distribution of pathogenic mutations in NSCLC patients (N = 72) ...
A study by IRB Barcelona reveals that transfer RNA (tRNA) genes accumulate mutations at a frequency up to nine times higher ...
Researchers engineered a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.
Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung ...
Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...
As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research from Boston Children's ...
Rezatapopt is a first-in-class oral therapy designed to target the TP53 Y220C mutation. This mutation affects the p53 protein ...
Zacks Investment Research on MSN
BDTX: What silevertinib data say about EGFR NSCLC upside
Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results